Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®â¯ (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting
Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2]ZYMFENTRA®